Traders should monitor upcoming medical conferences for mature survival data, which could serve as a major catalyst. The current release confirms safety but provides no efficacy signal — next data readout is critical for valuation upside.
Price Chart
Executive Summary
Can-Fite BioPharma announced positive safety results from its Phase IIa trial of namodenoson in advanced pancreatic cancer, meeting the primary endpoint of safety with no new safety signals. While survival data (OS/PFS) remain immature, the drug continues to show a favorable tolerability profile in a heavily pretreated population, supporting further development. The company plans to disclose mature survival outcomes at upcoming scientific meetings.
Key Facts
- Phase IIa trial of namodenoson in advanced pancreatic cancer met primary safety endpoint.
- 20 patients enrolled, all previously treated; no new safety signals observed.
- Secondary endpoints (OS, PFS) not yet mature — 1/3 of patients still alive at data cutoff.
- Namodenoson has FDA Orphan Drug Designation for pancreatic cancer.
- Survival follow-up ongoing; full results expected at future scientific meetings.
Financial Impact
No immediate financial impact — trial was safety-focused with no efficacy data yet. Future efficacy readouts could significantly impact valuation.
Risk Factors
- Immature efficacy data — survival outcomes may not show clinical benefit.
- Small sample size (n=20) limits statistical power.
- Biotech clinical-stage stocks are highly volatile and sensitive to binary trial outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249198 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.68 (−13.77%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.68 (+13.77%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.68 (+13.77%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.68 (+26.89%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.68 (−23.22%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.68 (−28.45%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.68 (−28.75%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.68 (+28.75%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.68 (−28.75%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.68 (−53.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers